Fibrinogen and the Risk of Thrombosis
Fibrinogen and the Risk of Thrombosis
复制标题
DOI：
10.1055/s-0030-1248720
复制
发表时间：
2010-02-01
影响因子：
5.7
通讯作者：
Neerman-Arbez, Marguerite
中科院分区：
文献类型：
--
作者：
de Moerloose, Philippe;Boehlen, Francoise;Neerman-Arbez, Marguerite
纤维蛋白原以不同方式促进血栓形成风险。事实上，纤维蛋白原基因中的各种突变易患血栓形成。同时，高水平的纤维蛋白原也与血栓性并发症有关。尽管潜在的致病机制尚不清楚，但这很可能涉及相关的炎症和高凝状态。在过去的几年中，特别注意力集中在纤维蛋白原基因的多态性参与增加纤维蛋白原水平或纤维蛋白原的质的变化。异常纤维蛋白原血症和血栓形成风险之间的关联是众所周知的，并且一些机制已被明确确定。特别是，一些患有低纤维蛋白原血症或无纤维蛋白原血症的患者也可能患有严重的血栓栓塞并发症。这些患者的管理特别具有挑战性，因为他们不仅有血栓形成的风险，而且还有出血的风险。本文综述了与血栓形成相关的纤维蛋白原的各种定量和定性缺陷，可能预测血栓形成风险的测试，以及一些预防或治疗方法。
Fibrinogen contributes to thrombosis risk in different ways. Indeed, various mutations in the fibrinogen genes predispose to thrombosis. At the same time, high levels of fibrinogen are also associated with thrombotic complications. Although the underlying causative mechanisms are not clear, this most likely involves the associated inflammatory and hypercoagulable states. In the last few years, particular attention has focused on the polymorphisms of fibrinogen genes involved in increased fibrinogen levels or fibrinogen qualitative changes. The association between dysfibrinogenemia and risk of thrombosis is well known, and some mechanisms have been clearly identified. Paradoxically, some patients with either hypofibrinogenemia or afibrinogenemia may also suffer from severe thromboembolic complications. The management of these patients is particularly challenging because they are not only at risk of thrombosis but also of bleeding. This review discusses the various quantitative and qualitative defects of fibrinogen associated with thrombosis, the tests that may predict the thrombotic risk, as well as some preventive or therapeutic approaches.